Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates.

Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in ...

By Kathy Gaillard Pastor Richard D. Shaw grew up in Marion, AL, in the same birthplace of civil rights icons Coretta Scott King and Andrew Young’s wife (Jean Childs Young). […] ...

Understanding the type and stage of cancer is crucial for developing effective treatment plan. Here's what a surgical oncologist wants you to know.

Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with ...

Ahmedabad (Gujarat) [India], August 6: Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung ...

This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact ...

A person’s risk of developing lung cancer may increase with increasing consumption of ultra-processed foods, a new study suggests.

When 1965 began, federal voting rights legislation was far from the minds of most in Washington. After all, Congress had just ...

Intas Pharmaceuticals has introduced Hetronifly (serplulimab) in the Indian market. The therapy is the first PD-1 inhibitor ...

Heavy smoking is the most common cause of small cell lung cancer, but it's not the only one. Check out the risk factors for ...